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Abstract
Background: An ideal tumor vaccine should activate both effector and memory immune response against tumor-
specific antigens. Beside the CD8+ T cells that play a central role in the generation of a protective immune
response and of long-term memory, dendritic cells (DCs) are important for the induction, coordination and
regulation of the adaptive immune response. The DCs can conduct all of the elements of the immune orchestra
and are therefore a fundamental target and tool for vaccination. The present study was aimed at assessing the
ability of tumor vaccine composed of C-class CpG ODNs and irradiated melanoma tumor cells B16F1 followed by
two additional injections of CpG ODNs to induce the generation of a functional long-term memory response in
experimental tumor model in mice (i.p. B16F1).
Results: It has been shown that the functional memory response in vaccinated mice persists for at least 60 days
after the last vaccination. Repeated vaccination also improves the survival of experimental animals compared to
single vaccination, whereas the proportion of animals totally protected from the development of aggressive i.p.
B16F1 tumors after vaccination repeated three times varies between 88.9%-100.0%. Additionally, the long-term
immune memory and tumor protection is maintained over a prolonged period of time of at least 8 months.
Finally, it has been demonstrated that following the vaccination the tumor-specific memory cells predominantly
reside in bone marrow and peritoneal tissue and are in a more active state than their splenic counterparts.
Conclusions: In this study we demonstrated that tumor vaccine composed of C-class CpG ODNs and irradiated
tumor cells followed by two additional injections of CpG ODNs induces a long-term immunity against aggressive
B16F1 tumors.
Background
Dendritic cells (DCs) play a crucial role in linking innate
and adaptive immunity and consequently in the genera-
tion of a protective immune response against tumors
[1]. The DCs as the most potent antigen presenting cells
(APCs) are responsible for recognition and processing of
tumor antigens, and they function as important initia-
tors and modulators of the specific and lasting immune
response against tumor antigens [1-3]. The ability of
DCs to steer the immune response from the generation
of effector and memory cells to the induction of periph-
eral tolerance is directed through their production of
different cytokines such as TNF-a, IL-6, IL-12 and type
I IFNs upon stimulation of specific receptors. In view of
that the early signals given by the DCs can determine
the scope and nature of the immune response [1,2]. The
proper activation and maturation of the DCs is conse-
quently crucial for the induction of an effective immune
response against tumor cells. It has been demonstrated
that “danger” signals are essential pre-requisites for the
maturation and activation of DCs into powerful antigen
presenting cells [1,3,4]. Synthetic CpG oligodeoxynucle-
tides (CpG ODNs) contain unmethylated CpG motifs
similar to those observed in bacterial DNA. They act as
“danger” signals that trigger the maturation of DCs
[5-7]. Through binding on Toll-like receptor 9 (TLR9)
the CpG ODNs induce an elevated expression of MHC
I and II molecules as well as of co-stimulatory molecules
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present tumor antigens to T and B effector cells [8,9].
Besides, the CpG ODNs induce in the DCs and other
APCs a secretion of different cytokines including TNF-
a, IL-6, IL-12, IL-18 and IFNs (IFN-a,I F N - b) [1,10,11].
In this way, the CpG ODNs indirectly activate natural
killer (NK) cells and cytotoxic T lymphocytes (CTL) in
addition to antigen-specific, antibody-producing B cells.
Among different classes of CpG ODNs with
immuno-stimulatory activities, the B-class CpG ODNs
(which are strong B cell stimulators but poor inducers
of IFN-a in DCs) are the ones used in nearly all of
t h ev a c c i n es t u d i e sp e r f o r m e dt od a t ea n da r em o r e
advanced in clinical application in oncology being
tested in phase II and phase III clinical trials as cancer
vaccine adjuvant and in combined therapies [6,10-16].
However, C-class CpG ODNs (that stimulate B cells
and induce intensive type I IFN production by DCs)
have also shown the vaccine adjuvant activity [17,18].
For example, in study performed by Wille-Reece, the
nonhuman primates vaccinated with HIV Gag protein/
Montanide and C-class CpG ODNs or the TLR7/8
agonist (3M-012) had higher frequencies of Th1
response after primary immunization compared to
other vaccine groups immunized only with HIV Gag
protein/Montanide or with HIV Gag protein/Monta-
nide and TLR8 agonist 3M-002 [17]. In our previous
study, we demonstrated a significant preventive anti-
tumor immunity achieved through the vaccination
with irradiated melanoma tumor cells B16F1 and C-
class CpG ODNs followed by two additional injections
of CpG ODNs. The proportion of protected mice ran-
ged from 75% to 100%. Additionally, in more than
80% of survivors, a long-lasting immunity has been
triggered [19]. Class C CpG ODNs were also shown to
suppress the growth of s.c. B16F1 tumors when
applied as a single agent and to remarkably enhance
the anti-tumor effect of tumor irradiation in combined
therapy [20].
The determination of the manner by which the long-
lived cellular immune response is generated following
vaccination and of the mechanism by which memory
cells are maintained over time is important in the devel-
o p m e n to fas a f ea n de f f e c t i v et u m o rv a c c i n e .I nt h i s
article, we sought to investigate whether the tumor vac-
cine composed of C-class CpG ODNs and irradiated
melanoma B16F1 tumor cells followed by two additional
injections of CpG ODNs could induce a functional
long-term memory response. Additionally, we evaluated
the duration of the long-lasting protection as well as the
distribution and homing of the long-lived memory cells
after immunization with different vaccination settings.
For this purpose we chose a weakly immunogenic
B16F1 tumor model.
Results
The achieved antitumor protection in repeatedly
vaccinated mice lasts at least 60 days
In this part, we investigated the longevity of the induced
antitumor protection. For that purpose, the experimen-
tal mice had been once, twice or three times pre-vacci-
nated 90, 60 or 30 days before they were challenged
with viable tumor cells (day 0) (see Figure 1).
The average survival was statistically significantly pro-
longed after the application of the tumor vaccine and
two additional injections of CpG ODNs in all experi-
mental groups compared to the mock treated control
group (p < 0.001; Figure 2; Table 1). In a fraction of
mice that had been vaccinated twice and three times,
the antitumor protection was upgraded in comparison
to mice immunized only once. Namely, the proportion
of protected mice ranged from 28.6% to 38.1% in case
of a single vaccination and it increased to 68.2% - 75.0%
in groups vaccinated twice and to 88.9%-100.0% in
groups vaccinated three times (Table 1). The day of the
first tumor vaccine application did not influence the
survival of animals significantly. Convincing antitumor
preventive effect was accomplished with the triple
(applied three times) vaccination irrespective of the day
of first vaccine application (p = 0.377).
The vaccine (followed by two additional injections of
CpG ODNs) applied two or three times also significantly
prolonged the survival of mice in comparison to a single
vaccination (p = 0.023; p < 0.001 respectively; Table 1).
Again the most persuasive effect was achieved with the
vaccine applied three times irrespective of the day of
first application. There was no difference in survival
between the triple vaccination starting 90 days before
tumor challenge and the triple vaccination starting
30 days before tumor challenge (p = 0.413).
Figure 1 Time schedule of i.p. applications of the tumor
vaccine and viable tumor cells. The day of MNCs collection is
indicated.
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must be applied at least two times to achieve a func-
tional memory response and subsequently the tumor
rejection.
The long-lasting protective antitumor immunity is
generated in survivors
In order to answer the question for how long the pre-
vaccinated mice are protected against the tumorigenic
effect of viable tumor cells, mice that had been preven-
tively vaccinated and had already survived one tumor
challenge were re-challenged with viable tumor cells
100 days after the first tumor challenge without any
additional treatment (see Figure 3). It is obvious from
Table 2 and Figure 4 that in more than 60.0% of mice
having survived the first tumor challenge the long-last-
ing immunity was induced. The proportion of survivors
after the second tumor challenge was higher in mice
vaccinated two or three times (at least 75.0%) yet not
significantly when compared to a single vaccination (p =
0.452). Hence, the proportions of survivors were evenly
distributed among the experimental groups. These
results suggest that memory cells specific for the tumor
antigens persist in vaccinated animals for at least
8 months following the immunization with tumor
vaccine and two additional injections of CpG ODNs.
Long-lived memory T cells home predominantly to bone
marrow and to peritoneal tissue
In this part, we investigated the activation and specificity
of the memory response along with the distribution of
memory cells after vaccination. For this purpose, the
MNCs were isolated from bone marrow, spleen and
peritoneal lavage. They were grown for additional 5 days
with or without tumor antigens (irradiated B16F1 tumor
cells) to have ultimately their cytotoxicity against B16F1
tumor cells assessed by cytotoxicity assay.
The data presented in Figure 5A indicate that the
cytotoxicity of MNCs isolated from bone marrow was
increased in mice vaccinated 90 and 60 days before
tumor challenge compared to mice vaccinated 30 days
before tumor challenge. The cytotoxicity of bone mar-
row MNCs was significantly upgraded after two or three
vaccinations starting 90 or 60 days before tumor chal-
lenge in comparison to mice vaccinated two or three
Figure 2 Time schedule of re-challenge with 5 × 10
5 viable
B16F1 tumor cells of pre-vaccinated mice surviving the first
tumor challenge. * vaccination started 90 days before the first
injection of viable tumor cells; the vaccine was applied once (1×),
twice (2×) or three times (3×) in 15 days interval ** vaccination
started 60 days before the first injection of viable tumor cells; the
vaccine was applied once (1×), twice (2×) or three times (3×) in 15
days interval *** vaccination started 30 days before the first
injection of viable tumor cells; the vaccine was applied once (1×),
twice (2×) in 15 days interval or three times (3×) in 15 days interval,
except for the last vaccination, which was performed 7 days after
second vaccination.
Table 1 The antitumor preventive effect of the tumor vaccine composed of irradiated tumor cells and CpG ODNs
Group Number of mice
a Number of survivors
b Proportion of survivors (%) Average survival AM ± SE (days) p-value
c p-value
d
Control 22 0 0.0 16.09 ± 1.14
1 × 90d* 21 8 38.1 60.38 ± 8.21 <0.0001
2 × 90d* 20 14 75.0 85.30 ± 5.97 <0.0001 0.012
3 × 90d* 21 19 90.5 94.38 ± 3.93 <0.0001 0.003
1 × 60d** 21 6 28.6 51.00 ± 7.86 <0.0001
2 × 60d** 22 16 72.7 82.82 ± 6.69 <0.0001 0.002
3 × 60d** 18 16 88.9 89.10 ± 5.12 <0.0001 <0.001
1 × 30d*** 22 7 31.8 62.14 ± 7.60 <0.0001
2 × 30d*** 22 15 68.2 81.00 ± 6.66 <0.0001 0.022
3 × 30d*** 20 20 100.0 100.00 ± 0.00 <0.0001 0.003
The vaccine was composed of 1 × 10
6 irradiated B16F1 tumor cells and 30 μg of CpG ODNs; each vaccine administration was followed by two additional
injections of CpG ODNs (2 and 4 days after vaccine administration).
a number of animals included in the experimental group
b surviving animals - are animals which survived at least 100 days after tumor challenge
c p-value: group compared to control group
d p-value: group compared to group vaccinated once starting the same day prior to tumor challenge
* vaccination started 90 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval
** vaccination started 60 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval
*** vaccination started 30 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) in 15 days interval or three times (3×) in
15 days interval, except for the last vaccination, which was performed 7 days after second vaccination
The experiment was repeated three times.
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Additionally, in mice receiving the vaccine three times
starting 90 or 60 days before tumor challenge, a statisti-
cally significant augmentation of cytotoxicity was deter-
mined compared to a single vaccination starting at the
same time (p = 0.007; p = 0.004 respectively). There was
also a significant difference between the cytotoxicity of
MNCs from mice treated with the tumor vaccine twice
and cytotoxicity of MNCs from mice vaccinated three
times starting on day 90 (p = 0.043), whereas this differ-
ence was not observed in mice starting the vaccination
on day 60 or 30 prior to tumor challenge (p = 0.474;
p = 0.071 respectively).
In Figure 5B, the cytotoxicity of MNCs isolated from
peritoneal cavity is presented. The cytotoxicity of these
cells was enhanced by increasing the number of vaccina-
tions irrespectively of the day of first vaccine applica-
tion. The statistically significant enhancement of
cytotoxicity was determined when tumor vaccine was
applied two and three times starting 90, 60 or 30 days
prior to tumor challenge in comparison to the cytotoxi-
city of MNCs obtained from mice vaccinated just once
(Table 4).
The Figure 5C shows the cytotoxicity of splenic
MNCs. The cytotoxicity was decreased with the longer
time interval between the first day of vaccination and
MNCs collection, since the cytotoxicity in mice vacci-
nated 90 days before MNCs collection was significantly
reduced compared to mice vaccinated 30 days before
MNCs collection (p = 0.003). The cytotoxicity of splenic
MNCs was unaffected by the number of vaccinations.
Nevertheless, the cytotoxicity of splenic MNCs was
Figure 3 Survival of vaccinated mice challenged i.p. with 5 ×
10
5 viable B16F1 tumor cells. Mice were immunized with tumor
vaccine composed of 1 × 10
6 B16F1 irradiated tumor cells and 30
μg of CpG ODNs, followed by two additional injections of 30 μgo f
CpG ODNs 2 and 4 days after tumor vaccine application. The tumor
vaccine was first applied on day 90, day 60 or day 30 prior to viable
tumor cell inoculation (day 0). The tumor vaccine was administrated
once (1×), twice (2×) and three times (3×) in 15 days period.
Control: mock treated; 1 × 90: vaccine + two additional injections of
CpG ODNs applied once 90 days before tumor inoculation; 2 × 90:
vaccine + two additional injections of CpG ODNs applied twice 90
and 75 days before tumor inoculation; 3 × 90: vaccine + two
additional injections of CpG ODNs applied three times 90, 75 and
60 days before tumor inoculation; 1 × 60: vaccine + two additional
injections of CpG ODNs applied once 60 days before tumor
inoculation; 2 × 60: vaccine + two additional injections of CpG
ODNs applied twice 60 and 45 days before tumor inoculation; 3 ×
60: vaccine + two additional injections of CpG ODNs applied three
times 60, 45 and 30 days before tumor inoculation; 1 × 30: vaccine
+ two additional injections of CpG ODNs applied once 30 days
before tumor inoculation; 2 × 30: vaccine + two additional
injections of CpG ODNs applied twice 30 and 15 days before tumor
inoculation; 3 × 30: vaccine + two additional injections of CpG
ODNs applied three times 30, 15 and 7 days before tumor
inoculation. The experiment was repeated three times.
Table 2 Long-term protection of mice surviving the i.p. challenge with viable tumor cells
Group Number of mice
a Proportion of survivors (%)
b Average survival AM ± SE (days) p-value
c
Control 27 0.0 18.00 ± 1.14
1 × 90d* 8 75.0 83.75 ± 10.96 <0.0001
2 × 90d* 14 85.7 92.86 ± 4.91 <0.0001
3 × 90d* 19 73.7 90.89 ± 4.25 <0.0001
1 × 60d** 6 66.7 73.00 ± 17.08 <0.0001
2 × 60d** 16 87.5 92.50 ± 5.35 <0.0001
3 × 60d** 16 81.3 90.19 ± 5,63 <0.0001
1 × 30d*** 7 57.1 79.14 ± 12.10 <0.0001
2 × 30d*** 15 80.0 94.20 ± 12.38 <0.0001
3 × 30d*** 20 100.0 100.00 ± 0.00 <0.0001
Mice surviving the i.p. challenge with 5 × 10
5 B16F1 viable tumor cells were re-challenged with the same number of viable tumor cells without additional
treatment.
a number of animals which survived 100 days after first tumor challenge
b surviving animals - are animals which survived at least 100 days after tumor challenge
c p-value: group compared to control group
* vaccination started 90 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval
** vaccination started 60 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days interval
*** vaccination started 30 days before the injection of viable tumor cells; the vaccine was applied once (1×), twice (2×) in 15 days interval or three times (3×) in
15 days interval, except for the last vaccination, which was performed 7 days after second vaccination
The experiment was repeated three times.
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marrow or peritoneal lavage (p = 0.002).
The cytotoxicity assay confirms that the functional
memory is generated after two and three vaccinations.
Memory cells predominantly home to bone marrow and
to peritoneal tissue.
Discussion
In our previous study we demonstrated that significant
antitumor immunity was generated through the vaccina-
tion of mice with CpG ODNs in combination with irra-
diated tumor cells (tumor vaccine) followed by two
additional injections of CpG ODNs. We confirmed also
that for the improvement of the in vivo effect additional
injections of CpG ODNs in form of maintenance mono-
therapy are essential. A long-lasting presence of CpG
ODNs is therefore required for assuring the maturation
of APCs during a longer period of time and the required
signal for maturation of an adequate number of DCs
can be provided only by prolongation of treatment with
CpG ODNs [19].
Figure 4 Survival curves of mice re-challenged i.p. with 5 × 10
5
viable B16F1 tumor cells. Pre-vaccinated mice surviving the first
tumor challenge were without any additional treatment re-
challenged 100 days after the first tumor challenge. Control: mock
treated; 1 × 90: vaccine + two additional injections of CpG ODNs
applied once 90 days before tumor inoculation; 2 × 90: vaccine +
two additional injections of CpG ODNs applied twice 90 and 75
days before tumor inoculation; 3 × 90: vaccine + two additional
injections of CpG ODNs applied three times 90, 75 and 60 days
before tumor inoculation; 1 × 60: vaccine + two additional
injections of CpG ODNs applied once 60 days before tumor
inoculation; 2 × 60: vaccine + two additional injections of CpG
ODNs applied twice 60 and 45 days before tumor inoculation; 3 ×
60: vaccine + two additional injections of CpG ODNs applied three
times 60, 45 and 30 days before tumor inoculation; 1 × 30: vaccine
+ two additional injections of CpG ODNs applied once 30 days
before tumor inoculation; 2 × 30: vaccine + two additional
injections of CpG ODNs applied twice 30 and 15 days before tumor
inoculation; 3 × 30: vaccine + two additional injections of CpG
ODNs applied three times 30, 15 and 7 days before tumor
inoculation. The experiment was repeated three times.
Figure 5 The cytotoxicitiy of MNCs (AM ± SD) isolated from
bone marrow (A), peritoneal lavage (B) and spleen (C). Bone
marrow, peritoneal lavages and spleens from pre-vaccinated mice
were collected on day 0 and subsequently MNCs were isolated. Half
of the MNCs from each experimental group were re-exposed to the
antigen - irradiated B16F1 tumor cells and another half was grown
without any additional stimulation for 5 days. The cytotoxicity of
MNCs was determined as described in Materials and methods and
was normalized against the control (mock) treated group. 1×:
vaccine + two additional injections of CpG ODNs applied once 90,
60 or 30 days before tumor inoculation; 2×: vaccine + two
additional injections of CpG ODNs applied twice 90 and 75 days
before tumor inoculation, 60 and 45 days before tumor inoculation
or 30 and 15 days before tumor inoculation; 3×: vaccine + two
additional injections of CpG ODNs applied three times 90, 75 and
60 days before tumor inoculation, 60, 45 and 30 days before tumor
inoculation or 30, 15 and 7 days before tumor inoculation.
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tumor vaccine composed of C-class CpG ODNs and irra-
diated melanoma B16F1 tumor cells followed by two addi-
tional injections of CpG ODNs could induce a functional
long-term memory response. Further we planned to evalu-
ate the duration of the long-lasting protection as well as
the distribution and homing of long-lived memory cells
after immunization with different vaccination settings.
With the initial experiments we confirmed that a func-
tional memory response is induced upon vaccination with
tumor vaccine composed of irradiated B16F1 tumor cells
and C-class CpG ODNs followed by two additional injec-
tions of CpG ODNs. A substantial antitumor immunity
was achieved in all experimental mice immunized with the
tumor vaccine compared to control (mock treated) mice
(p < 0.001). The induced long-lasting preventive effect was
additionally improved when the vaccination with CpG
ODNs in combination with irradiated tumor cells was
repeated two or three times. The proportion of animals
totally protected from the development of aggressive i.p.
B16F1 tumors after vaccination repeated three times
ranged from 88.9% to 100.0%. These results suggested that
the repeated vaccination was more effective in generating
a durable antitumor response than a single vaccination.
Similarly, in the study of Wu and Fleischmann, it was
reported that after repeated vaccination of mice with a
tumor vaccine (composed of irradiated B16 melanoma
cells exposed in vitro to long-term IFN-alpha treatment) a
protective durable immunity against a second tumor chal-
lenge was significantly increased [21,22]. Our results are
also in agreement with the statements of other authors
that short-term or weak antigen stimulation can trigger
the initial proliferation of effector T cells but is insufficient
to trigger the long-lived memory T cells [23-25]. On the
other hand, the higher number of vaccinations resulted in
a repeatedly longer lasting presence of CpG ODNs, which
were in turn able to activate a sufficient number of APCs
capable of inducing the memory cell development.
The duration of immune response was explored from
different views. Firstly - by changing the interval between
vaccination and challenge with viable tumor cells.
Secondly - by changing the number of vaccine applica-
tions and thirdly - by assessing the effectiveness of
immune response in surviving mice without additional
vaccination. Our results showed no difference in survival
of mice being vaccinated three times but starting at
different days: 90, 60 or 30 days before tumor challenge
(p = 0.413). Yet, significantly longer survival was
observed among mice vaccinated two or three times and
those vaccinated just once. These outcomes suggest that
a strong antitumor immunity in vaccinated mice persists
for at least 60 days after the last vaccination. Our results
are also in accordance with results reported by Mahnke
et al., who showed that 66.0% of vaccinated nude mice
did not develop tumors after high-dose i.v. tumor chal-
lenge more than 2 months after adoptive immunotherapy
[26]. The cells involved in long-term immune protection
were memory cells by definition as tumor challenge
occurred more than 2 months after the initial effector
phase had subsided. It was confirmed that the mainte-
nance of functional long-term CD8+ T-cell memory is
independent of antigen persistence, although the contin-
uous presence of antigen results in the boosting of anti-
gen-specific T-cell numbers [26]. In our study, the
repeated vaccinations might have favored the generation
and maintenance of tumor-specific CD8+ T-cell memory
pools.
The next question in the study was about the duration
of the antitumor prevention assured by the vaccination.
Addressing this question, the experimental mice that had
survived the first tumor challenge were re-challenged
with the same type of viable tumor cells (100 days after
Table 3 The significantly increased cytotoxicity of bone
marrow MNCs obtained from mice pre-vaccinated 90 and
60 days prior to MNCs collection
Group p-value
a p-value
b p-value
c
1 × 90d* 0.014 0.031 0.011
2 × 90d* 0.016 0.023 0.002
3 × 90d* 0.001 0.002 <0.001
1 × 60d** 0.478 0.664 0.245
2 × 60d** 0.007 0.012 <0.001
3 × 60d** 0.001 0.003 <0.001
a p-value: group compared to group vaccinated once 30 days before tumor
challenge
b p-value: group compared to group vaccinated twice: 30 and 15 days before
tumor challenge
c p-value: group compared to group vaccinated three times: 30, 15 and 7 days
before tumor challenge
* vaccination started 90 days before the injection of viable tumor cells; the
vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days
interval
** vaccination started 60 days before the injection of viable tumor cells; the
vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days
interval
Table 4 The cytotoxicity of MNCs from peritoneal tissue
was significantly enhanced after repeated vaccinations
Group 2 ×
90d*
3×
90d*
2×
60d**
3×
60d**
2×
30d***
3×
30d***
p-value
a 0.024 0.004 0.056 0.004 0.006 <0.001
a p-value: group compared to group vaccinated once 90, 60 or 30 days before
tumor challenge
* vaccination started 90 days before the injection of viable tumor cells; the
vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days
interval
** vaccination started 60 days before the injection of viable tumor cells; the
vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days
interval
*** vaccination started 30 days before the injection of viable tumor cells; the
vaccine was applied once (1×), twice (2×) or three times (3×) in 15 days
interval, except for the last - third vaccination, which was performed 7 days
after second vaccination
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observed that in more than 60.0% of survivors a long-
lasting immunity was induced. The number of survivors
developing the long-lasting immunity did not depend
upon the number of repeated vaccinations. These results
indicate that the activation of a critical number of APCs
had been accomplished when mice were treated with the
vaccine composed of irradiated tumor cells and C-class
CpG ODNs and two additional applications of CpG
ODNs. The first functional response and the proliferative
expansion of T lymphocytes after the vaccination were
accompanied by the differentiation of specific memory T
lymphocytes functioning as long-term memory T cells
and enabling the long-lasting immunity [19]. Our results
suggest that the long-term immune memory and tumor
protection could be maintained over a prolonged period
of time - at least 8 months. The comparable duration of
long term memory and tumor protection after adoptive
transfer of memory peritoneal exudate cells from donors
to recipients was earlier reported by Mahnke et al. [26].
I nt h el a s tp a r to fo u re x p e r i m e n t s ,w ei n v e s t i g a t e d
the homing place of memory T cell pool following
vaccination. Using the cytotoxicity assay, we con-
firmed that MNCs isolated from bone marrow and
peritoneal lavage are more cytotoxic against B16F1
tumor cells than their counterparts in spleen. This is
in agreement with the reports of other investigators,
who described a higher frequency and higher cytotoxi-
city of antigen-specific memory T cells in the bone
marrow compared to spleen, lymph nodes or periph-
eral blood [26-28]. Mahnke et al. showed that the
bone marrow microenvironment has special features
that are of importance for the maintenance of tumor
dormancy and immunological T-cell memory, and that
a low level of persisting antigen favors the mainte-
nance of antigen-specific memory T cells over irrele-
vant memory T cells [26]. On the other hand, Parretta
et al. demonstrated that the bone marrow acts as a
suitable microenvironment for the antigen-indepen-
dent proliferation of memory CD8+ cells (primarily
cytokine driven) and plays a relevant role in the main-
tenance of T cell memory [28]. The presence of anti-
tumor CTLs in the bone marrow of untreated breast
cancer patients which has been associated with the
local control of micrometastasis growth might also be
due to the preferential maintenance of memory CD8+
cells in the bone marrow [28]. In the light of above
findings, our results revealed that after a prolonged
period following the vaccination (2-3 months) memory
cells from the bone marrow and peritoneal tissue were
in a more active state than those from the spleen.
This could firstly be explained by the observation that
in the bone marrow memory CD8+ cells might receive
survival/proliferation signals sustaining the long-term
maintenance of these cells. Indeed, the stromal cells
and cells of the hematopoietic lineage in the bone
marrow produce both IL-7 and IL-15 that stimulate
the CD8+ cell survival and proliferation [28,29]. Sec-
ondly, it was suggested that the optimal preservation
of T-cell memory requires the presence of the DCs.
Cavanagh et al. showed that a small number of differ-
entiated DCs traffics constitutively from peripheral tis-
sue to blood and that these circulating DCs have a
considerable bone marrow tropism. Once in the bone
marrow, the DCs induce a rapid proliferation of anti-
gen-specific memory T cells [30]. In this view, the
repeated vaccination results in a higher number of
mature, tumor antigen-bearing DCs and therefore
could act in “boosting” of memory responses against
tumor cells.
It is recognized that memory T cells are heteroge-
neous in terms of both homing capacity and effector
function [31,32]. This heterogeneity is reflected in the
current definition of central memory and effector mem-
ory T cells [31,32]. Effector memory T cells home to
peripheral tissues, they rapidly produce effector cyto-
k i n e ss u c ha sI F N - g upon antigenic stimulation, but
have limited proliferative capacity. Our results indicate
that following immunization with tumor vaccine the
migration of memory T cells to the bone marrow bears
obvious parallels with homing of memory T-cell into
peritoneal tissue. Recent reports have shown high levels
of constitutive memory T-cell lodging into extra-lym-
phoid organs in the absence of overt inflammation, and
it has been demonstrated that epithelial cells produce
homeostatic chemokines able to attract T lymphocytes
at the body surfaces [29]. Finally, our in vitro results
confirmed the results from in vivo experiments. The
tumor vaccine applied two or three times significantly
increased the cytotoxicity of MNCs isolated from bone
marrow and peritoneal lavage compared to single vacci-
nation. It is likely that the repeated injections of tumor
antigens in combination with CpG ODNs result in the
boosting of tumor-specific T-cell numbers and conse-
quently in memory cell pool enhancement. Opposingly,
the cytotoxicity of splenic MNCs was not significantly
influenced by the number of vaccinations indicating
again that the bone marrow is the superior compart-
ment for harboring of tumor-specific memory cells. This
correlates with previous reports of memory T-cell
enrichment in the bone marrow of experimental animals
and cancer patients [33] and also with a higher extent of
retention of circulating DCs in the bone marrow com-
pared to spleen [30].
Conclusions
In conclusion, we demonstrated that tumor vaccine
composed of C-class CpG ODNs and irradiated tumor
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ODNs induces a long-term immunity against aggressive
B16F1 tumors. Repeated vaccination improves the survi-
val of experimental animals compared to a single vacci-
nation. A functional response is induced for at least 60
days and the long-term immune memory and tumor
protection can be maintained over a prolonged period
of time (at least 8 months). Following vaccination,
tumor-specific memory cells predominantly reside in
bone marrow and peritoneal tissue being in a more
active state than their splenic counterparts.
Methods
Cell lines
Murine B16F1 melanoma cells (American Type Culture
Collection, ATCC, Rockville, MD) were grown in Eagle’s
minimal essential medium (EMEM) supplemented with
10% FCS (Sigma St. Louis, MO), penicillin (100 units/ml,
Pfizer, New York, NY), streptomycin (100 μg/ml, Pfizer)
and gentamycin (11 μg/ml, Invenex, Charing Falls, OH).
Animal tumor model
The experiments were performed on 8 - 10 weeks old
syngeneic female C57Bl/6 mice (Institute of Pathology,
University of Ljubljana, SLO). Experimental animals were
kept in standard animal colony at a natural day/night
cycle. At least 6 healthy animals without signs of fungal
or other infections, and with normal body weight, were
included in each experimental group. Intraperitoneal
(i.p.) B16F1 tumor model was employed. Tumors were
induced by i.p. inoculation of 5 × 10
5 viable B16F1 tumor
cells in 0.2 ml EMEM supplemented with 2% FCS. The
day of tumor cells inoculation was considered as day 0.
The animals were monitored for the day of death and the
proportion of survivors was noted. The average survival
(AM) ± standard deviation (SD) ± standard error (SE)
was calculated for the animals that ultimately developed
tumors and consequently died of them. The experiment
was performed (repeated) three times.
The experiments were approved by the Ministry of
Agriculture, Forestry and Food of the Republic of Slove-
nia (permission No. 34401-35/2008/12).
Vaccine preparation
Tumor vaccine was composed of 1 × 10
6 B16F1 irra-
diated tumor cells and 30 μg of CpG ODN 2395 class C
(Coley Pharmaceutical, Ontario, CA) per mouse.
Tumor cell preparation: B16F1 tumor cells were tryp-
sinized (0.25% trypsin, Sigma) and washed three times
in the 10% serum-containing medium. The tumor pel-
lets were than resuspended in the 2% serum containing
EMEM (in concentration of 1 × 10
6 cells/cm
2) and irra-
diated sublethally with 60 Gy on Darpac 2000x X-ray
unit (Gulmay Medical Ltd., Shepperton, UK). Tumor
cells, which were neither clonogenic in vitro,n o r
tumorigenic in vivo were taken as sublethally irradiated.
Vaccine and CpG ODN administration
The experimental mice were treated with the tumor
vaccine i.p. followed by two additional injections of 30
μg of CpG ODNs (i.p.) 2 and 4 days after vaccine
administration. The treatment schedule was as follows:
the vaccine followed by two additional CpG ODNs
applications was applied once, twice or three times
starting on days 90, 60 or 30 prior to the injection of
viable tumor cells (day 0). When the vaccine was admi-
nistered two or three times the interval between the
administrations was 15 days, except in the case of last
administration in the group of animals treated three
times beginning on day 30 - this administration was just
7 days after the second administration. (Figure 1).
Evaluation of long-lasting immunity
Mice that have been preventively treated with the vaccine
in combination with two additional doses of CpG ODN
were challenged i.p. with 5 × 10
5 viable B16F1 tumor cells.
After 100 days, the survivors were re-challenged
with 5 × 10
5 viable tumor cells without additional pre-
vaccination (Figure 3).
Isolation of mouse MNCs from spleen, bone marrow and
peritoneal lavage
The spleens, femurs and peritoneal lavages were col-
l e c t e do nd a y0( F i g u r e1 ) .T h es p l e e n sw e r ec u ti n
small pieces and mechanically disrupted. The bone mar-
row was rinsed with EMEM from the femurs. The peri-
toneal cavity was rinsed two times with PBS and
peritoneal lavage was than centrifuged at 1500 rpm for
5 min and cell pellets were resuspended in EMEM.
MNCs were subsequently isolated by gradient centrifu-
gation on Ficoll (Amersham Pharmacia Biotech AB,
Uppsala, S) according to the manufacturer’s instructions.
The MNCs from three animals from the same group
were pooled together.
Determination of memory cells among the isolated MNCs
Isolated MNCs from vaccinated and control mice were
explored for the presence of memory cells by determi-
nation of antigen-activated T lymphocytes. Half of the
MNCs isolated from spleens, bone marrows or perito-
neal lavages in concentration 2 × 10
6/well were stimu-
lated in vitro for 5 days with irradiated B16F1 cells
(2 × 10
4/well), while the other half of MNCs
(2 × 10
6/well) were grown for 5 days without addi-
tional stimulation. The cytotoxicity on target B16F1
melanoma cells was determined.
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For the determination of cytotoxicity of MNCs, the
CytoTox® 96 non-radioactive cytotoxicity assay (Invitro-
gen, Carlsbad, California, USA) was used according to
the manufacturer’s instructions. In brief, 1 × 10
4/well
target cells (B16F1 melanoma cells) were cultured with
MNCs at the ratio of 1:10. The release of lactic dehy-
drogenase (LDH) from the target cells was quantified
through measuring of absorption (at 490nm) in formed
red formazan crystals. The percentage of cytotoxicity
was calculated by the formula: (experimental LDH -
LDH in the culture medium)/(total intracellular LDH -
LDH in the culture medium) x100 [34]. Experimental
LDH release represents LDH values obtained from tar-
get B16F1 tumor cells. The results were normalized
against control (mock) treated group.
Statistical analysis
The survival curves of in vivo experiments were plotted
by the method of Kaplan and Meier using GraphPad
Prism 3.0 software. Survival curves were compared
using the log-rank test. The p-value < 0.05 was consid-
ered as statistically significant. The in vitro results were
analyzed using SigmaStat 3.0 software. The average
mean (AM), standard deviation (SD) and standard error
(SE) for each group was determined using descriptive
statistics. The differences between the experimental
groups were determined using OneWay Anova. The
p-value < 0.05 was considered as statistically significant.
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